Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cullinan Therapeutics, Inc.

NASDAQ: CGEM · Life Sciences · 8 alerts · CIK 1789972

Share price
$9.50Close, Nov 16
Market cap
$617M
Shares outstanding
64.92MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cullinan Therapeutics, Inc. filings on SEC EDGAR ↗

6:03 AM ET 8-K
Business Update

Cullinan Therapeutics Business Update

Cullinan Therapeutics has initiated a rolling New Drug Application (NDA) submission to the FDA for zipalertinib in combination with chemotherapy for first-line treatment of NSCLC with EGFR exon 20 insertion mutations. The submission is being conducted under the FDA's Real-Time Oncology Review (RTOR) program and is supported by positive Phase 3 REZILIENT3 trial data. Completion of the submission is expected by year-end 2026, potentially triggering a $100 million milestone payment from partner Taiho upon approval.

Counterparty
FDA
7:30 AM ET 8-K
Business Update

Cullinan Therapeutics Business Update

Cullinan Therapeutics outlined its anticipated pipeline milestones for the fourth quarter of 2026, including data readouts for its T cell engager programs CLN-978, velinotamig, and CLN-049. The company plans to share multi-dose regimen data for CLN-978 across SLE, RA, and Sjögren’s disease in December, and velinotamig data at the ACR Convergence conference in November.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.